Navigation Links
Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
Date:10/8/2008

Review Zanolimumab Program to be Discontinued and Headcount to be Reduced Summary: Genmab Announces the Results of its Portfolio Review; Zanolimumab

Program to be Discontinued and the Company Will Reduce the Number of

Employees

COPENHAGEN, October 8 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that it is discontinuing development of zanolimumab (HuMax-CD4(R)). In addition, as a result of a portfolio review and assessment of the organization, Genmab is reducing its headcount by 101 positions.

As the company approaches potential commercialization, the need to establish a sustainable level of R&D investment is a key priority. Genmab has conducted a review of its portfolio and organization to establish priorities that will build the greatest potential value. The company will sharpen its focus on cancer therapeutics and a less broad, but higher potential portfolio.

Zanolimumab is currently in a Phase III pivotal study to treat cutaneous T-cell lymphoma (CTCL). As Genmab has previously indicated, patient recruitment into the zanolimumab pivotal study has been slow which the company believes is due to the relatively small market potential in CTCL, the introduction of a new CTCL therapeutic to the market and numerous competing clinical trials. In the light of these issues, Genmab considers that the significant investment required to take the product through to approval is no longer a good use of its resources.

Genmab will also aim to out-license three of its early stage development programs that fall outside the focus area: HuMax-HepC(TM), HuMax-IL8(TM) and HuMax-TAC(TM).

In addition, Genmab will wind down the zalutumumab (HuMax-EGFr(TM)) early stage studies in colorectal and lung cancer. This decision is based on new information about the role of K-RAS mutations and appropriate therapeutic regimens. Genmab will continue its development of two Phase III and two earlier stage
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genmab Announces Upcoming Ofatumumab Studies
2. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
3. Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
4. Genmab Reaches Milestone in Ofatumumab Collaboration
5. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
6. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
7. Genmab Announces Updates on Phase III Cancer Studies
8. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
9. Bionomics Achieves US$1 Million Milestone Payment from Genmab
10. DAHANCA Initiates Head and Neck Cancer Study With Genmabs HuMax-EGFr
11. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... for the fourth quarter of 2013 on Monday, February 3, ... release after the close of trading. (Logo: ... call to discuss the operating highlights and financial results for ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... VALHALLA, N.Y. , Jan. 14, 2014   Oligomerix, Inc. ... disease modifying therapeutics for Alzheimer,s disease (AD) and related ... headquarters to Valhalla, NY as ... additional laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Mich., June 17 GeneGo, Inc., a leading,provider ... announced,today that they were awarded a Phase I ... of a platform for functional data analysis in,cancer. ... Boston on the project. The system, MetaMiner (Oncology) ...
... SYDNEY, Australia, June 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; ... Limited to,manage and provide eligible patients worldwide with ... The program will allow patients who are unable ... are considered by their physician,to be suffering from ...
Cached Medicine Technology:GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer 2Pharmaxis Establishes Named Patient Program for Bronchitol 2
(Date:7/10/2014)... decades, health-conscious people around the globe have taken antioxidant ... was one of the paths to good health and ... of antioxidant supplements have repeatedly dashed the hopes of ... risk. Virtually all such trials have failed to ... in several trials antioxidant supplementation has been linked with ...
(Date:7/10/2014)... could prove useful in treating small cell lung cancer - ... the Cancer Research UK Manchester Institute, based at The University ... teamed up with experts at AstraZeneca, as part of a ... as AZD3965 - on small cell lung cancer cells. , ... , also helps identify which patients are most likely to ...
(Date:7/9/2014)... sudden, acute episodes of low back pain are not ... pressure, wind direction and precipitation. Findings published in ... American College of Rheumatology (ACR), indicate that the risk ... speed or wind gusts, but was not clinically significant. ... nearly everyone experiences low back pain at some point ...
(Date:7/9/2014)... After Susan Wakulich was told she had an aneurysm, ... ahead of her. , "I was devastated," said Wakulich, who ... "I knew this was a serious diagnosis. Then I met ... that involved a less invasive procedure. It was something I ... participating in a multi-center U.S. clinical trial to evaluate the ...
(Date:7/9/2014)... the metabolism of stromal support cells and immune cells ... cell types in the development of diseases could ... cancer. That was the conclusion of a review article ... leading journal Nature . , Prof. Peter Carmeliet: ... The metabolism of cancer cells has been examined in ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2
... difficile Inpatients on Any One Day; Patients,Dispersed Across ... The life-threatening,bacterium that causes diarrhea and more serious ... than previously,estimated, according to a new study released ... and Epidemiology (APIC)., "The National Prevalence Study ...
... web site by pilots, for pilots, www.wings4aviators.com , custom-embroiders U.S. ... To honor veterans, the company is donating 10% of the proceeds ... 501(c)(3) charity. , ... Hartland, WI (PRWEB) November 11, ...
... nursing, The Magnet Prize, was awarded to Abington Memorial Hospital (AMH) for ... Lake City, UT. This was the sixth year the award was ... ... the most prestigious awards in nursing, The Magnet Prize, was awarded to ...
... to helping seniors and their families understand their Medicare benefits ... hosting eight "Knowing Your Medicare Benefits for 2009" comparison presentations ... ... Torrance, CA (PRWEB) November 11, 2008 ...
... recognized as one of the top performing California physician groups by ... is one of only four California Physicians groups in the greater ... ... (PRWEB) November 11, 2008 -- This is the fifth straight year ...
... unveils TX11: a mobile computing cart designed to accommodate most laptop ... ... -- The Columbus, OH based medical product developer, Artromick, announced that ... mobile computing carts : the TX11 Medserver. While all Artromick ...
Cached Medicine News:Health News:Intestinal Infection Afflicts 13 of 1,000 Hospital Patients, Infection Rates 6.5 - 20 Times Greater Than Previous Estimates, New Study Says 2Health News:Intestinal Infection Afflicts 13 of 1,000 Hospital Patients, Infection Rates 6.5 - 20 Times Greater Than Previous Estimates, New Study Says 3Health News:New Web Site Offers Shirts with Custom-embroidered Aviator Wings for Veteran Military Pilots, Supports Families of the Wounded Fund 2Health News:New Web Site Offers Shirts with Custom-embroidered Aviator Wings for Veteran Military Pilots, Supports Families of the Wounded Fund 3Health News:New Web Site Offers Shirts with Custom-embroidered Aviator Wings for Veteran Military Pilots, Supports Families of the Wounded Fund 4Health News:Abington Memorial One of Just Six Hospitals in the U.S. to Win Magnet Prize 2Health News:Abington Memorial One of Just Six Hospitals in the U.S. to Win Magnet Prize 3Health News:Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations 2Health News:Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations 3Health News:Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations 4Health News:HealthCare Partners Rated A 'Top Performing California Physician Group' By IHA For the Fifth Straight Year 2Health News:HealthCare Partners Rated A 'Top Performing California Physician Group' By IHA For the Fifth Straight Year 3Health News:Mobile Computing Carts Leader to Release New Clinical Computer Cart 2
Mac Pherson titanium tying forceps are ergonomic, very thin, angled with tying platforms. Round ergonomic design for great balance and feel. Fine platforms excellent for tying 10-0 suture....
Fine tying forceps, standard with smooth jaws. For 7-0 to 9-0 sutures....
Harms tying forceps, standard, straight with smooth jaws. For 7-0 to 9-0 sutures....
Tennant stainless steel tying forceps is extra delicate, straight with smooth jaws, 6 mm long platform, round handle with guide pin. For 9-0 to 11-0 sutures....
Medicine Products: